Heartbeam, Inc. current report, 31 January 2022

Full document

HeartBeam, Inc. — Form 8-K Summary

Business Context and Reporting Period

HeartBeam, Inc. filed this current report on February 2, 2022, regarding events occurring primarily on January 31, 2022. The filing concerns a new partnership with LIVMOR, Inc. to develop a company-branded remote patient monitoring platform and the termination of HeartBeam’s prior development agreement with Ximedica, LLC.

Key Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial statement metrics. It states that HeartBeam will pay LIVMOR development fees in two equal installments, but does not disclose the fee amount.

Material Changes Versus the Prior Comparable Period

  • On January 31, 2022, HeartBeam entered into a three-year partnership agreement with LIVMOR, subject to automatic renewal unless terminated under the agreement.
  • LIVMOR will customize a company-branded version of its Halo+ cloud-based remote monitoring portal, referred to as the HeartBeam Platform.
  • The HeartBeam Platform is intended to be an FDA-registered Class 1 system supporting remote patient monitoring, telehealth, cybersecurity, software engineering, and human-factors requirements.
  • HeartBeam terminated its August 2, 2021 agreement with Ximedica, which covered services related to finalizing the development of HeartBeam’s initial products for FDA 510(k) submission. The termination was acknowledged as complete on January 31, 2022.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Management indicated that the LIVMOR partnership supports the project schedule for an FDA submission for HeartBeam’s initial heart-attack detection software solution in an emergency-department setting.
  • LIVMOR will provide defined development services, project management, and regulatory support intended to assist HeartBeam in obtaining FDA clearance.
  • The filing does not provide a specific FDA submission date, clearance probability, commercialization timeline, revenue outlook, or financial guidance.
  • The partnership’s development, regulatory, and commercialization objectives remain subject to execution risks and FDA review and clearance.
  • The filing states that the disclosed agreement descriptions are summaries; the complete terms are contained in the filed exhibits.

Important Facts for Investors to Verify

  • Review Exhibit 10.1 for the LIVMOR partnership’s development-fee amounts, milestones, termination provisions, intellectual-property rights, and other obligations.
  • Confirm the scope and status of the planned FDA submission and the regulatory classification of the HeartBeam Platform.
  • Assess how terminating the Ximedica agreement affects development responsibilities, timing, costs, and any remaining obligations.
  • Monitor future filings for material cash commitments, operating results, financing needs, and updates on FDA clearance or commercialization.
  • Review Exhibit 99.1 for additional management commentary regarding the LIVMOR partnership.